The genetics of uveal melanoma: An emerging framework for targeted therapy

Pigment Cell and Melanoma Research

Volumn 25, Issue 2, 2012, Pages 171-181

  Harbour, J William ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BAP1; Eye; GNA11; GNAQ; Melanoma; Metastasis

Indexed keywords

B RAF KINASE; BRCA1 PROTEIN; HISTONE DEACETYLASE; HYDROXAMIC ACID; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOLIPASE C; PROTEIN KINASE C; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER PROGNOSIS; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 3; CHROMOSOME 6P; CHROMOSOME 6Q; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; DIAGNOSTIC ACCURACY; DIPLOIDY; GENE EXPRESSION PROFILING; GENE INTERACTION; GENE LOCATION; GENE LOCUS; GENE MUTATION; GENETIC SCREENING; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; KARYOTYPE; MALIGNANT MESOTHELIOMA; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TETRAPLOIDY; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; UBIQUITINATION; UVEA MELANOMA;

ANIMALS; CHROMOSOME ABERRATIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MELANOMA; MICRORNAS; MOLECULAR TARGETED THERAPY; UVEAL NEOPLASMS;

EID: 84857443037     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2012.00979.x     Document Type: Article

References (137)

1. Aalto, Y., Eriksson, L., Seregard, S., Larsson, O., and Knuutila, S. (2001). Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest. Ophthalmol. Vis. Sci. 42, 313-317.
2. Abdel-Rahman, M.H., Yang, Y., Zhou, X.P., Craig, E.L., Davidorf, F.H., and Eng, C. (2006). High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J. Clin. Oncol. 24, 288-295.
3. Abdel-Rahman, M.H., Pilarski, R., Cebulla, C.M., Massengill, J.B., Christopher, B.N., Boru, G., Hovland, P., and Davidorf, F.H. (2011). Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J. Med. Genet. 48, 856-859.
4. Augsburger, J.J., and Gamel, J.W. (1990). Clinical prognostic factors in patients with posterior uveal malignant melanoma. Cancer 66, 1596-1600.
5. Augsburger, J.J., Correa, Z.M., and Shaikh, A.H. (2009). Effectiveness of treatments for metastatic uveal melanoma. Am. J. Ophthalmol. 148, 119-127.
6. Bastian, B.C., Leboit, P.E., Hamm, H., Brocker, E.B., and Pinkel, D. (1998). Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 58, 2170-2175.
7. Bauer, J., Kilic, E., Vaarwater, J., Bastian, B.C., Garbe, C., and De Klein, A. (2009). Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br. J. Cancer 101, 813-815.
8. Bernstein, B.E., Kamal, M., Lindblad-Toh, K. et al. (2005). Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120, 169-181.
9. Blasi, M.A., Roccella, F., Balestrazzi, E., Del Porto, G., De Felice, N., Roccella, M., Rota, R., and Grammatico, P. (1999). 3p13 region: a possible location of a tumor suppressor gene involved in uveal melanoma. Cancer Genet. Cytogenet. 108, 81-83.
10. Bommi, P.V., Dimri, M., Sahasrabuddhe, A.A., Khandekar, J., and Dimri, G.P. (2010). The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors. Cell Cycle 9, 2663-2673.
11. Bott, M., Brevet, M., Taylor, B.S. et al. (2011). The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 43, 668-672.
12. Brantley Jr, M.A., and Harbour, J.W. (2000a). Deregulation of the Rb and p53 pathways in uveal melanoma. Am. J. Pathol. 157, 1795-1801.
13. Brantley Jr, M.A., and Harbour, J.W. (2000b). Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. Cancer Res. 60, 4320-4323.
14. Canning, C.R., and Hungerford, J. (1988). Familial uveal melanoma. Br. J. Ophthalmol. 72, 241-243.
15. Chana, J.S., Wilson, G.D., Cree, I.A., Alexander, R.A., Myatt, N., Neale, M., Foss, A.J., and Hungerford, J.L. (1999). c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br. J. Ophthalmol. 83, 110-114.
16. Chang, S.H., Worley, L.A., Onken, M.D., and Harbour, J.W. (2008). Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res. 18, 191-200.
17. Chen, X., Wang, J., Shen, H., Lu, J., Li, C., Hu, D.N., Dong, X.D., Yan, D., and Tu, L. (2011). Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 52, 1193-1199.
18. Coleman, K., Baak, J.P., Van Diest, P.J., Curran, B., Mullaney, J., Fenton, M., and Leader, M. (1995). DNA ploidy status in 84 ocular melanomas: a study of DNA quantitation in ocular melanomas by flow cytometry and automatic and interactive static image analysis. Hum. Pathol. 26, 99-105.
19. Coupland, S.E., Bechrakis, N., Schuler, A., Anagnostopoulos, I., Hummel, M., Bornfeld, N., and Stein, H. (1998). Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. Br. J. Ophthalmol. 82, 961-970.
20. Coupland, S.E., Anastassiou, G., Stang, A., Schilling, H., Anagnostopoulos, I., Bornfeld, N., and Stein, H. (2000). The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J. Pathol. 191, 120-126.
21. Cross, N.A., Murray, A.K., Rennie, I.G., Ganesh, A., and Sisley, K. (2003). Instability of microsatellites is an infrequent event in uveal melanoma. Melanoma Res. 13, 435-440.
22. Cross, N.A., Ganesh, A., Parpia, M., Murray, A.K., Rennie, I.G., and Sisley, K. (2006). Multiple locations on chromosome 3 are the targets of specific deletions in uveal melanoma. Eye 20, 476-481.
23. Cruz 3rd, F., Rubin, B.P., Wilson, D., Town, A., Schroeder, A., Haley, A., Bainbridge, T., Heinrich, M.C., and Corless, C.L. (2003). Absence of BRAF and NRAS Mutations in Uveal Melanoma. Cancer Res. 63, 5761-5766.
24. Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147.
25. Damato, B.E., Dopierala, J., Klaasen, A., Van Dijk, M., Sibbring, J., and Coupland, S. (2009). Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest. Ophthalmol. Vis. Sci. 50, 3048-3055.
26. Damato, B., Dopierala, J.A., and Coupland, S.E. (2010). Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin. Cancer Res. 16, 6083-6092.
27. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
28. De La Cruz Jr, P.O., Specht, C.S., and Mclean, I.W. (1990). Lymphocytic infiltration in uveal malignant melanoma. Cancer 65, 112-115.
29. Diaz-Flores, E., and Shannon, K. (2007). Targeting oncogenic Ras. Genes Dev. 21, 1989-1992.
30. Diener-West, M., Reynolds, S.M., Agugliaro, D.J. et al. (2005). Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative Ocular Melanoma Study Group Report No. 26. Arch. Ophthalmol. 123, 1639-1643.
31. Egan, K.M., Seddon, J.M., Glynn, R.J., Gragoudas, E.S., and Albert, D.M. (1988). Epidemiologic aspects of uveal melanoma. Surv. Ophthalmol. 32, 239-251.
32. Ehlers, J.P., and Harbour, J.W. (2005). NBS1 expression as a prognostic marker in uveal melanoma. Clin. Cancer Res. 11, 1849-1853.
33. Ehlers, J.P., Worley, L., Onken, M.D., and Harbour, J.W. (2005). DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma. Clin. Cancer Res. 11, 3609-3613.
34. Ehlers, J.P., Worley, L., Onken, M.D., and Harbour, J.W. (2008). Integrative genomic analysis of aneuploidy in uveal melanoma. Clin. Cancer Res. 14, 115-122.
35. Folberg, R., Pe'er, J., Gruman, L.M., Woolson, R.F., Jeng, G., Montague, P.R., Moninger, T.O., Yi, H., and Moore, K.C. (1992). The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum. Pathol. 23, 1298-1305.
36. Gallagher, R.P., Elwood, J.M., Rootman, J., Spinelli, J.J., Hill, G.B., Threlfall, W.J., and Birdsell, J.M. (1985). Risk factors for ocular melanoma: Western Canada Melanoma Study. J. Natl Cancer Inst. 74, 775-778.
37. Gamel, J.W., Mclean, I.W., Foster, W.D., and Zimmerman, L.E. (1978). Uveal melanomas: correlation of cytologic features with prognosis. Cancer 41, 1897-1901.
38. Ghazvini, S., Char, D.H., Kroll, S., Waldman, F.M., and Pinkel, D. (1996). Comparative genomic hybridization analysis of archival formalin-fixed paraffin-embedded uveal melanomas. Cancer Genet. Cytogenet. 90, 95-101.
39. Gordon, K.B., Thompson, C.T., Char, D.H., O'brien, J.M., Kroll, S., Ghazvini, S., and Gray, J.W. (1994). Comparative genomic hybridization in the detection of DNA copy number abnormalities in uveal melanoma. Cancer Res. 54, 4764-4768.
40. Griffin, C.A., Long, P.P., and Schachat, A.P. (1988). Trisomy 6p in an ocular melanoma. Cancer Genet. Cytogenet. 32, 129-132.
41. Harbour, J.W., Onken, M.D., Roberson, E.D., Duan, S., Cao, L., Worley, L.A., Council, M.L., Matatall, K.A., Helms, C., and Bowcock, A.M. (2010). Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410-1413.
42. Hausler, T., Stang, A., Anastassiou, G., Jockel, K.H., Mrzyk, S., Horsthemke, B., Lohmann, D.R., and Zeschnigk, M. (2005). Loss of heterozygosity of 1p in uveal melanomas with monosomy 3. Int. J. Cancer 116, 909-913.
43. Henriquez, F., Janssen, C., Kemp, E.G., and Roberts, F. (2007). The T1799A BRAF mutation is present in iris melanoma. Invest. Ophthalmol. Vis. Sci. 48, 4897-4900.
44. Hoglund, M., Gisselsson, D., Hansen, G.B., White, V.A., Sall, T., Mitelman, F., and Horsman, D. (2004). Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution. Int. J. Cancer 108, 57-65.
45. Horsman, D.E., Sroka, H., Rootman, J., and White, V.A. (1990). Monosomy 3 and isochromosome 8q in a uveal melanoma. Cancer Genet. Cytogenet. 45, 249-253.
46. Horsthemke, B., Prescher, G., Bornfeld, N., and Becher, R. (1992). Loss of chromosome 3 alleles and multiplication of chromosome 8 alleles in uveal melanoma. Genes Chromosom. Cancer 4, 217-221.
47. Hughes, S., Damato, B.E., Giddings, I., Hiscott, P.S., Humphreys, J., and Houlston, R.S. (2005). Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3. Br. J. Cancer 93, 1191-1196.
48. Iscovich, J., Abdulrazik, M., Cour, C., Fischbein, A., Pe'er, J., and Goldgar, D.E. (2002). Prevalence of the BRCA2 6174 del T mutation in Israeli uveal melanoma patients. Int. J. Cancer 98, 42-44.
49. Jensen, D.E., and Rauscher 3rd, F.J. (1999). BAP1, a candidate tumor suppressor protein that interacts with BRCA1. Ann. N Y Acad. Sci. 886, 191-194.
50. Jensen, D.E., Proctor, M., Marquis, S.T. et al. (1998). BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16, 1097-1112.
51. Karlsson, M., Boeryd, B., Carstensen, J., Kagedal, B., and Wingren, S. (1995). DNA ploidy and S-phase fraction as prognostic factors in patients with uveal melanomas. Br. J. Cancer 71, 177-181.
52. Kath, R., Hayungs, J., Bornfeld, N., Sauerwein, W., Hoffken, K., and Seeber, S. (1993). Prognosis and treatment of disseminated uveal melanoma. Cancer 72, 2219-2223.
53. Kilic, E., Naus, N.C., Van Gils, W. et al. (2005). Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest. Ophthalmol. Vis. Sci. 46, 2253-2257.
54. Kilic, E., Van Gils, W., Lodder, E., Beverloo, H.B., Van Til, M.E., Mooy, C.M., Paridaens, D., De Klein, A., and Luyten, G.P. (2006). Clinical and cytogenetic analyses in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 47, 3703-3707.
55. Kilic, E., Bruggenwirth, H.T., Meier, M., Naus, N.C., Beverloo, H.B., Meijerink, J.P., Luyten, G.P., and De Klein, A. (2008). Increased expression of p73Deltaex2 transcript in uveal melanoma with loss of chromosome 1p. Melanoma Res. 18, 208-213.
56. Kujala, E., Makitie, T., and Kivela, T. (2003). Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma. Invest. Ophthalmol. Vis. Sci. 44, 4651-4659.
57. Landreville, S., Agapova, O.A., and Harbour, J.W. (2008). Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncol. 4, 629-636.
58. Landreville, S., Agapova, O.A., Matatall, K.A., Kneass, Z.T., Onken, M.D., Lee, R.S., Bowcock, A.M., and Harbour, J.W. (2012). Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin. Cancer Res. 18, 408-416.
59. Machida, Y.J., Machida, Y., Vashisht, A.A., Wohlschlegel, J.A., and Dutta, A. (2009). The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J. Biol. Chem. 284, 34179-34188.
60. Makitie, T., Summanen, P., Tarkkanen, A., and Kivela, T. (2001). Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 42, 1414-1421.
61. Malaponte, G., Libra, M., Gangemi, P., Bevelacqua, V., Mangano, K., D'amico, F., Mazzarino, M.C., Stivala, F., Mccubrey, J.A., and Travali, S. (2006). Detection of BRAF gene mutation in primary choroidal melanoma tissue. Cancer Biol. Ther. 5, 225-227.
62. McGarvey, K.M., Van Neste, L., Cope, L., Ohm, J.E., Herman, J.G., Van Criekinge, W., Schuebel, K.E., and Baylin, S.B. (2008). Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer Res. 68, 5753-5759.
63. McNamara, M., Felix, C., Davison, E.V., Fenton, M., and Kennedy, S.M. (1997). Assessment of chromosome 3 copy number in ocular melanoma using fluorescence in situ hybridization. Cancer Genet. Cytogenet. 98, 4-8.
64. Merbs, S.L., and Sidransky, D. (1999). Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma. Invest. Ophthalmol. Vis. Sci. 40, 779-783.
65. Mitsiades, N., Chew, S.A., He, B., Riechardt, A.I., Karadedou, T., Kotoula, V., and Poulaki, V. (2011). Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest. Ophthalmol. Vis. Sci. 52, 7248-7255.
66. Mooy, C.M., Van Der Helm, M.J., Van Der Kwast, T.H., De Jong, P.T., Ruiter, D.J., and Zwarthoff, E.C. (1991). No N-ras mutations in human uveal melanoma: the role of ultraviolet light revisited. Br. J. Cancer 64, 411-413.
67. Myatt, N., Aristodemou, P., Neale, M.H., Foss, A.J., Hungerford, J.L., Bhattacharya, S., and I, A.C. (2000). Abnormalities of the transforming growth factor-beta pathway in ocular melanoma. J. Pathol. 192, 511-518.
68. Naus, N.C., Zuidervaart, W., Rayman, N., Slater, R., Van Drunen, E., Ksander, B., Luyten, G.P., and Klein, A. (2000). Mutation analysis of the PTEN gene in uveal melanoma cell lines. Int. J. Cancer 87, 151-153.
69. Naus, N.C., Van Drunen, E., De Klein, A., Luyten, G.P., Paridaens, D.A., Alers, J.C., Ksander, B.R., Beverloo, H.B., and Slater, R.M. (2001). Characterization of complex chromosomal abnormalities in uveal melanoma by fluorescence in situ hybridization, spectral karyotyping, and comparative genomic hybridization. Genes Chromosom. Cancer 30, 267-273.
70. Ohta, M., Berd, D., Shimizu, M., Nagai, H., Cotticelli, M.G., Mastrangelo, M., Shields, J.A., Shields, C.L., Croce, C.M., and Huebner, K. (1996). Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int. J. Cancer 65, 762-767.
71. Onken, M.D., Worley, L.A., Ehlers, J.P., and Harbour, J.W. (2004). Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 64, 7205-7209.
72. Onken, M.D., Ehlers, J.P., Worley, L.A., Makita, J., Yokota, Y., and Harbour, J.W. (2006a). Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res. 66, 4602-4609.
73. Onken, M.D., Worley, L.A., Davila, R.M., Char, D.H., and Harbour, J.W. (2006b). Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens. J. Mol. Diagn. 8, 567-573.
74. Onken, M.D., Worley, L.A., Person, E., Char, D.H., Bowcock, A.M., and Harbour, J.W. (2007). Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin. Cancer Res. 13, 2923-2927.
75. Onken, M.D., Worley, L., and Harbour, J.W. (2008a). A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis. Clin. Cancer Res. 14, 3737-3745.
76. Onken, M.D., Worley, L.A., Long, M.D., Duan, S., Council, M.L., Bowcock, A.M., and Harbour, J.W. (2008b). Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 49, 5230-5234.
77. Onken, M.D., Worley, L.A., Tuscan, M.D., and Harbour, J.W. (2010). An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J. Mol. Diagn. 12, 461-468.
78. Onken, M., Worley, L., Char, D. et al. (in press). Collaborative Ocular Oncology Group Report No. 1: prospective Validation of a Multi-Gene Prognostic Assay in Uveal Melanoma. Ophthalmology.
79. Pache, M., Glatz, K., Bosch, D. et al. (2003). Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. Virchows Arch. 443, 741-744.
80. Papadopoulos, S., Benter, T., Anastassiou, G., Pape, M., Gerhard, S., Bornfeld, N., Ludwig, W.D., and Dorken, B. (2002). Assessment of genomic instability in breast cancer and uveal melanoma by random amplified polymorphic DNA analysis. Int. J. Cancer 99, 193-200.
81. Parrella, P., Sidransky, D., and Merbs, S.L. (1999). Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway. Cancer Res. 59, 3032-3037.
82. Parrella, P., Caballero, O.L., Sidransky, D., and Merbs, S.L. (2001). Detection of c-myc Amplification in Uveal Melanoma by Fluorescent In Situ Hybridization. Invest. Ophthalmol. Vis. Sci. 42, 1679-1684.
83. Parrella, P., Fazio, V.M., Gallo, A.P., Sidransky, D., and Merbs, S.L. (2003). Fine mapping of chromosome 3 in uveal melanoma: identification of a minimal region of deletion on chromosomal arm 3p25.1-p25.2. Cancer Res. 63, 8507-8510.
84. Patel, K.A., Edmondson, N.D., Talbot, F., Parsons, M.A., Rennie, I.G., and Sisley, K. (2001). Prediction of prognosis in patients with uveal melanoma using fluorescence in situ hybridisation. Br. J. Ophthalmol. 85, 1440-1444.
85. Patel, M., Smyth, E., Chapman, P.B., Wolchok, J.D., Schwartz, G.K., Abramson, D.H., and Carvajal, R.D. (2011). Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin. Cancer Res. 17, 2087-2100.
86. Petrausch, U., Martus, P., Tonnies, H. et al. (2008). Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye 22, 997-1007.
87. Prescher, G., Bornfeld, N., and Becher, R. (1990). Nonrandom chromosomal abnormalities in primary uveal melanoma. J. Natl Cancer Inst. 82, 1765-1769.
88. Prescher, G., Bornfeld, N., Friedrichs, W., Seeber, S., and Becher, R. (1995). Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation. Cancer Genet. Cytogenet. 80, 40-46.
89. Prescher, G., Bornfeld, N., Hirche, H., Horsthemke, B., Jockel, K.H., and Becher, R. (1996). Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347, 1222-1225.
90. Ramaiya, K.J., and Harbour, J.W. (2007). Current management of uveal melanoma. Expert Rev. Ophthalmol. 2, 939-946.
91. Rimoldi, D., Salvi, S., Lienard, D., Lejeune, F.J., Speiser, D., Zografos, L., and Cerottini, J.C. (2003). Lack of BRAF Mutations in Uveal Melanoma. Cancer Res. 63, 5712-5715.
92. Saraiva, V.S., Caissie, A.L., Segal, L., Edelstein, C., and Burnier Jr, M.N. (2005). Immunohistochemical expression of phospho-Akt in uveal melanoma. Melanoma Res. 15, 245-250.
93. Scheuermann, J.C., De Ayala Alonso, A.G., Oktaba, K., Ly-Hartig, N., Mcginty, R.K., Fraterman, S., Wilm, M., Muir, T.W., and Muller, J. (2010). Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 465, 243-247.
94. Scholes, A.G., Liloglou, T., Maloney, P., Hagan, S., Nunn, J., Hiscott, P., Damato, B.E., Grierson, I., and Field, J.K. (2001). Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 42, 2472-2477.
95. Scholes, A.G., Damato, B.E., Nunn, J., Hiscott, P., Grierson, I., and Field, J.K. (2003). Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest. Ophthalmol. Vis. Sci. 44, 1008-1011.
96. Scott, R.J., Vajdic, C.M., Armstrong, B.K., Ainsworth, C.J., Meldrum, C.J., Aitken, J.F., and Kricker, A. (2002). BRCA2 mutations in a population-based series of patients with ocular melanoma. Int. J. Cancer 102, 188-191.
97. Seddon, J.M., Gragoudas, E.S., Glynn, R.J., Egan, K.M., Albert, D.M., and Blitzer, P.H. (1990). Host factors, UV radiation, and risk of uveal melanoma. A case-control study. Arch. Ophthalmol. 108, 1274-1280.
98. Singh, A.D., Boghosian-Sell, L., Wary, K.K., Shields, C.L., De Potter, P., Donoso, L.A., Shields, J.A., and Cannizzaro, L.A. (1994). Cytogenetic findings in primary uveal melanoma. Cancer Genet. Cytogenet. 72, 109-115.
99. Singh, A.D., Croce, C.M., Wary, K.K., Shields, J.A., Donoso, L.A., Shields, C.L., Huebner, K., and Ohta, M. (1996a). Familial uveal melanoma: absence of germline mutations involving the cyclin-dependent kinase-4 inhibitor gene (p16). Ophthalmic Genet. 17, 39-40.
100. Singh, A.D., Shields, C.L., De Potter, P., Shields, J.A., Trock, B., Cater, J., and Pastore, D. (1996b). Familial uveal melanoma. Clinical observations on 56 patients. Arch. Ophthalmol. 114, 392-399.
101. Singh, A.D., Bergman, L., and Seregard, S. (2005a). Uveal melanoma: epidemiologic aspects. Ophthalmol. Clin. North Am. 18, 75-84, viii.
102. Singh, A.D., Kalyani, P., and Topham, A. (2005b). Estimating the risk of malignant transformation of a choroidal nevus. Opthalmology 112, 1784-1789.
103. Singh, A.D., Turell, M.E., and Topham, A.K. (2011). Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 118, 1881-1885.
104. Sinilnikova, O.M., Egan, K.M., Quinn, J.L., Boutrand, L., Lenoir, G.M., Stoppa-Lyonnet, D., Desjardins, L., Levy, C., Goldgar, D., and Gragoudas, E.S. (1999). Germline brca2 sequence variants in patients with ocular melanoma. Int. J. Cancer 82, 325-328.
105. Sisley, K., Rennie, I.G., Cottam, D.W., Potter, A.M., Potter, C.W., and Rees, R.C. (1990). Cytogenetic findings in six posterior uveal melanomas: involvement of chromosomes 3, 6, and 8. Genes Chromosom. Cancer 2, 205-209.
106. Sisley, K., Curtis, D., Rennie, I.G., and Rees, R.C. (1993). Loss of heterozygosity of the thyroid hormone receptor B in posterior uveal melanoma. Melanoma Res. 3, 457-461.
107. Sisley, K., Rennie, I.G., Parsons, M.A., Jacques, R., Hammond, D.W., Bell, S.M., Potter, A.M., and Rees, R.C. (1997). Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosom. Cancer 19, 22-28.
108. Soparker, C.N., O'brien, J.M., and Albert, D.M. (1993). Investigation of the role of the ras protooncogene point mutation in human uveal melanomas. Invest. Ophthalmol. Vis. Sci. 34, 2203-2209.
109. Soufir, N., Bressac-De Paillerets, B., Desjardins, L., Levy, C., Bombled, J., Gorin, I., Schlienger, P., and Stoppa-Lyonnet, D. (2000). Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes. Br. J. Cancer 82, 818-822.
110. Speicher, M.R., Prescher, G., Du Manoir, S., Jauch, A., Horsthemke, B., Bornfeld, N., Becher, R., and Cremer, T. (1994). Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization. Cancer Res. 54, 3817-3823.
111. Sun, Y., Tran, B.N., Worley, L.A., Delston, R.B., and Harbour, J.W. (2005). Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 46, 1561-1564.
112. Testa, J.R., Cheung, M., Pei, J. et al. (2011). Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022-1025.
113. Toyota, M., Ohe-Toyota, M., Ahuja, N., and Issa, J.P. (2000). Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc. Natl. Acad. Sci. U S A 97, 710-715.
114. Tschentscher, F., Prescher, G., Zeschnigk, M., Horsthemke, B., and Lohmann, D.R. (2000). Identification of chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. Cancer Genet. Cytogenet. 122, 13-17.
115. Tschentscher, F., Prescher, G., Horsman, D.E. et al. (2001). Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma. Cancer Res. 61, 3439-3442.
116. Tschentscher, F., Husing, J., Holter, T. et al. (2003). Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 63, 2578-2584.
117. Tucker, M.A., Shields, J.A., Hartge, P., Augsburger, J., Hoover, R.N., and Fraumeni Jr, J.F. (1985). Sunlight exposure as risk factor for intraocular malignant melanoma. N. Engl. J. Med. 313, 789-792.
118. Tyagi, S., Chabes, A.L., Wysocka, J., and Herr, W. (2007). E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol. Cell 27, 107-119.
119. Van Der Velden, P.A., Metzelaar-Blok, J.A., Bergman, W., Monique, H., Hurks, H., Frants, R.R., Gruis, N.A., and Jager, M.J. (2001). Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res. 61, 5303-5306.
120. Van Dijk, M.C., Rombout, P.D., Boots-Sprenger, S.H., Straatman, H., Bernsen, M.R., Ruiter, D.J., and Jeuken, J.W. (2005). Multiplex ligation-dependent probe amplification for the detection of chromosomal gains and losses in formalin-fixed tissue. Diagn. Mol. Pathol. 14, 9-16.
121. Van Gils, W., Lodder, E.M., Mensink, H.W., Kilic, E., Naus, N.C., Bruggenwirth, H.T., Van Ijcken, W., Paridaens, D., Luyten, G.P., and De Klein, A. (2008). Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis. Invest. Ophthalmol. Vis. Sci. 49, 4254-4262.
122. Van Hees, C.L., De Boer, A., Jager, M.J., Bleeker, J.C., Kakebeeke, H.M., Crijns, M.B., Vandenbroucke, J.P., and Bergman, W. (1994). Are atypical nevi a risk factor for uveal melanoma? A case-control study. J. Invest. Dermatol. 103, 202-205.
123. Van Raamsdonk, C.D., Fitch, K.R., Fuchs, H., De Angelis, M.H., and Barsh, G.S. (2004). Effects of G-protein mutations on skin color. Nat. Genet. 36, 961-968.
124. Van Raamsdonk, C.D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O'Brien, J.M., Simpson, E.M., Barsh, G.S., and Bastian, B.C. (2009). Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599-602.
125. Van Raamsdonk, C.D., Griewank, K.G., Crosby, M.B. et al. (2010). Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363, 2191-2199.
126. Ventii, K.H., Devi, N.S., Friedrich, K.L., Chernova, T.A., Tighiouart, M., Van Meir, E.G., and Wilkinson, K.D. (2008). BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 68, 6953-6962.
127. Weber, A., Hengge, U.R., Urbanik, D., Markwart, A., Mirmohammadsaegh, A., Reichel, M.B., Wittekind, C., Wiedemann, P., and Tannapfel, A. (2003). Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab. Invest. 83, 1771-1776.
128. White, V.A., Chambers, J.D., Courtright, P.D., Chang, W.Y., and Horsman, D.E. (1998). Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 83, 354-359.
129. Wiesner, T., Obenauf, A.C., Murali, R. et al. (2011). Germline mutations in BAP1 predispose to melanocytic tumors. Nat. Genet. 43, 1018-1021.
130. Wiltshire, R.N., Elner, V.M., Dennis, T., Vine, A.K., and Trent, J.M. (1993). Cytogenetic analysis of posterior uveal melanoma. Cancer Genet. Cytogenet. 66, 47-53.
131. Worley, L.A., Onken, M.D., Person, E., Robirds, D., Branson, J., Char, D.H., Perry, A., and Harbour, J.W. (2007). Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin. Cancer Res. 13, 1466-1471.
132. Worley, L.A., Long, M.D., Onken, M.D., and Harbour, J.W. (2008). Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res. 18, 184-190.
133. Young, L.H., Egan, K.M., Walsh, S.M., and Gragoudas, E.S. (1994). Familial uveal melanoma. Am. J. Ophthalmol. 117, 516-520.
134. Yucel, Y.H., Johnston, M.G., Ly, T. et al. (2009). Identification of lymphatics in the ciliary body of the human eye: a novel "uveolymphatic" outflow pathway. Exp. Eye Res. 89, 810-819.
135. Zeschnigk, M., Tschentscher, F., Lich, C., Brandt, B., Horsthemke, B., and Lohmann, D.R. (2003). Methylation Analysis of Several Tumour Suppressor Genes Shows a Low Frequency of Methylation of CDKN2A and RARB in Uveal Melanomas. Comp. Funct. Genomics 4, 329-336.
136. Zuidervaart, W., Van Der Velden, P.A., Hurks, M.H., Van Nieuwpoort, F.A., Out-Luiting, C.J., Singh, A.D., Frants, R.R., Jager, M.J., and Gruis, N.A. (2003). Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development. Br. J. Cancer 89, 1914-1919.
137. Zuidervaart, W., Van Nieuwpoort, F., Stark, M. et al. (2005). Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br. J. Cancer 92, 2032-2038.